Crossmark

Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis

Published Online: 2021-02-17

Published Print: 2021-09

Authors

Huang, X.

Chen, B.

Thabane, L.

Adachi, J.D.

Li, G. https://orcid.org/0000-0002-3472-8513
Funding

Funding for this research was provided by:

Science and Technology Program of Guangzhou (202002030252)

Science Foundation of Guangdong Second Provincial General Hospital (YY2018-002)

Doctoral workstation foundation of Guangdong Second Provincial general Hospital (2021BSGZ001)
License Information

Text and Data Mining valid from 2021-02-17

Version of Record valid from 2021-02-17
More Information

Article History

Received: 13 November 2020

Accepted: 29 January 2021

First Online: 17 February 2021

Declarations

:

: Not applicable

: Not applicable

: All authors read and approved the final manuscript for publication.

: JDA: grants/research support (Amgen, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Roche, Sanofi, and Wyeth), speaker’s bureau (Amgen), and consulting fees (Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi, Warner Chilcott, and Wyeth). The other authors declare that they have no conflicts of interest.

Document is current